DOCSLIB.ORG

Slide 1 Slide 2 Slide 3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Slide 1 Slide 2 Slide 3 Slide 1 Pharmacologic Treatment of Erectile Dysfunction Jeffrey Albaugh, PhD, APRN, CUCNS Director of Sexual Health NorthShore University Glenbrook Urology [email protected] Slide 2 Disclosures/Conflict of Interest • None Slide 3 Erectile Dysfunction • “The consistent or recurrent inability to attain and/or maintain a penile erection sufficient for sexual performance.” – WHO-ISIR. 1st International Consultation on ED, 1999 Slide 4 Male A&P Slide 5 Endothelial Dysfunction Slide 6 Oral Agents INTERVENTION: MEDICAL TREATMENTS - Oral Therapies PDE Type 5 inhibitors primary drug class - oral erectile dysfunction therapy Sildenafil (Viagra)-25-100mg Vardenafil (LeVitra) 5-20mg; Vardenafil (Staxyn) 10 mg Tadalafil (Cialis) 5-20mg, also 2.5-5 mg q day Avanafil (Stendra) 50-200mg Drugs are potent, selective inhibitors of type 5 phosphodiesterase - improve erectile function by inhibiting breakdown of cyclic GMP - smooth muscle relaxation enhanced Contraindicated with Nitrates, Teach Patient about Non-arteritic anterior ischemic optic neuropathy (NAION) Precautions with Alpha Blockers Slide 7 Sildenafil (Viagra) • Dosage: 25-100mg, starting dose 50 mg • Onset 30-60 mins; peak 60-120 minutes; mostly gone in 8-12 hours; reduced clearance in elderly (start low, go slow); empty stomach most sensitive to food! • Contraindications: – Pt. On any nitrates – Patients with retinitis pigmentosa • Precautions: Start @ 25 w/ >65y/o, Caution w/ CHF or MI within last 6 months, resting hypotension, if on alpha blockers start low and titrate up as needed; >3 drinks of alcohol • Side Effects – Headache, flushing, indigestion, dyspepsia, stuffiness, visual disturbances Slide 8 Sildenafil • Stop & seek medical help if visual acuity or hearing changes • Hepatic impairment- start low, go slow • Renal Insufficiency: Volunteers with mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment, the pharmacokinetics of 1 oral dose of VIAGRA (50 mg) were not altered. With severe (CLcr=<30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of concentrations compared to age-matched volunteers with no renal impairment. • In addition, N-desmethyl metabolite AUC and Cmax values significantly increased 200% and 79% respectively in subjects with severe renal impairment compared to subjects with normal renal function. – From prescribing information @ http://www.pfizer.com/files/products/uspi_viagra.pdf Slide 9 Vardenafil • Dosage: 5-20mg, Starting dose 10 mg • Contraindicated: – Patients on nitrates or guanylate cyclase stimulators (riociguat) – Not for patients with QT prolongation – Do not use with patients on dialysis as no research done (prescribing info) • Precautions: Start @ 5 mg if >64; Adjust dose or don’t use w/ moderate-severe renal impairment; start low, go slow with hepatic impairment; hypotension with excessive alcohol • Drug Interactions • Adverse Reactions: – Headache, flushing, stuffy nose, dizzy • Instruction – High fat may effect absorption, others similar Slide 10 Vardenafil Hcl • Do not take with nitrates • Caution with alpha- blockers=may drop your blood pressure to an unsafe level, must start at lowest dose- start low, go slow. • Metabolism through CYP3A4- ritonavir and indinavir increase half LeVitra- use 2.5mg no more than every 72 hours for ritonavir and 2.5 mg in 24 hours with indinavir • Erthromyacin & Ketoconazole- increase Levitra- use 2.5-5 mg dose Slide 11 Vardenafil Hcl • Do not use LEVITRA in patients on renal dialysis as vardenafil has not been evaluated in such patients. • No dosage adjustment is necessary in patients with creatinine clearance (CLcr) of 30–80 mL/min. In male volunteers with CLcr = 50-80 ml/min, the pharmacokinetics of vardenafil were similar to those observed in a control group with CLcr >80 mL/min. In male volunteers with CLcr = 30-50 mL/min or CLcr<30 mL/min, the AUC of vardenafil was 20–30% higher compared to that observed in a control group with CLcr>80 mL/min. – From prescribing information at http://www.levitra.com/assets/pdf/PI.pdf Slide 12 Tadalafil • Dosage: 5-20mg; Starting dose- 10mg; 36 hour duration • Onset 30-60 mins; peak effect- 60-120 mins • Contraindication: – Patients taking nitrates – Not recommended for men w/ MI last 90 days, stroke last 6 months, Class 2 or > heart failure; uncontrolled arrhythmias, hypotension <90/50 • Side Effects: – Headache, dyspepsia, dizziness, flushing, nasal stuffiness, back pain, myalgia – Teaching: Can take with foods, but high fat may delay absorption, same as others; no excessive alcohol (<5units) – Stop and seek medical help if visual acuity change or hearing loss Slide 13 Tadalafil • Renal Patients: • Patients with creatinine clearance 30 to 50 mL/min: Dosage adjustment may be needed. • Patients with creatinine clearance less than 30 mL/min or on hemodialysis: For use as needed: Dose should not exceed 5 mg every 72 hours. Once daily use is not recommended. – From prescribing info @ http://pi.lilly.com/us/cialis- pi.pdf Slide 14 Avanafil • Dosage: 50-200mg; starting dose 100mg • Onset 20 mins; peak effect 30-45 mins; Short 3 hour duration • Caution: alpha blockers- should be stable on them and then start with lowest dose and titrate as tolerated; if NAION • Can take with food, but delays absorption- empty stomach • Contraindication: – Patients taking nitrates- not within 12 hours • Side Effects: – Headache, flushing, nasal stuffiness, upper respiratory infection, back pain, dizziness – Teach to stop drug if changes in vision or hearing Slide 15 Avanafil • Not recommended in men with MI, stroke or life-threatening arrhythmia or coronary revascularization within last 6 months, Low BP < 90/50 or HTN >170/100; heart failure Class 2 or higher; angina with sex • No greater than 3 units of alcohol with avanafil • Start lower and may go to full dose in geriatric patients (caution depending on patient) • No data with severe renal or hepatic impairment Slide 16 Avanafil • Caution with alpha-blockers -may drop your blood pressure to an unsafe level, must start at lowest dose- start low, go slow. Caution with patients with left ventricular outflow obstruction or severely impaired autonomic BP control • Metabolism through CYP 450 isoform 3A4- Do not use stendra with drugs such as ketoconazole, clarithromyacin, ritonavir, atazanavir and indinavir, etc… • No higher than 50 mg maximum in 24 hours with erthromyacin, amprenavir, diltiazem, aprepitant, fluconazole, fosamprenavir and verapamil Slide 17 Comparison of Medications • No good head to head trials. • System review and network meta-analysis. 118 trials included (31,195 individuals). Tadalafil was most effective followed by vardenafil. Safety analysis did not reveal any differences amongst agents -Yuan, J et al. (2013). Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: A systemic…European Urology, 63(2013), 902-912 • A trade-off network meta-analysis of PDE-5 inhibitors for ED. 82 trials for efficacy and 72 for adverse events. Sildenafil 50 mg was treatment of choice for efficacy and tadalafil 10mg for tolerability. – Chen, L. et al. (2015). Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: A trade-off network meta-analysis. European Urology, 68(2015), 674-680. Slide 18 Treatment: MUSE Urethral suppository •Dosage: 125 to 1000 mcg •Onset: 5-10 mins; Duration 30-60mins •Contraindications: Hypersensitivity, Abnormally formed penis, conditions that can lead to priapism like sickle cell, multiple myeloma, leukemia, or if the patient has a penile implant •Caution if patient has low blood pressure or history of fainting •50% efficacy at best- may need to combine with orals •Adverse Reactions: penile pain, hypotension, prolonged erections, lightheadedness, or dizziness •http://www.muserx.com/pdf/muse-full-prescribing-information.pdf Slide 19 MUSE Always dose in the clinic and check vitals before and after medication Check applicator that medication present Keep penis upright during instillation process After administration, ensure that pellet delivered Roll penis for 10-30 seconds and watch tip to make sure pellet does come out of penis Walk to promote increased blood flow to penis Restrictive device placed at base of penis to decrease venous return from penis can not be on longer than 30 mins Lie down if dizzy, change positions slowly Do not give to patients with low blood pressure Slide 20 MUSE & Oral Agents • Oral agent 1 hour before MUSE • Synergistic effect improves efficacy • 23 patients unsatisfied w/ Sildenafil (100mg) alone, added MUSE 500mcg. 83% reported improved penile rigidity and sexual function, erection sufficient for penetration 80% of the time -Raina, R., Nandipati, K.C., et al. (2005). Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. Journal of Andrology, 26(6), 757-760. • 28 patients failed MUSE & Viagra as single agent- used MUSE 500mcg with sildenafil 100mg @ 30 months all 28 patients reported erections sufficient for penetration – Nebra, A. et al. (2002). Rationale for combination thereapy of intraurethral prostaglandin E1 & sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. International Journal of Impotence Research, 14 (Supp 1), S38-42. • 26 patients failed MUSE & Viagra as single agents- combo MUSE 500mcg & Sildenafil 100mg- Improved efficacy in combination -Nehra, A., Hakim, L.S., Barrett, D.M., Blute, M.L.,
Load more

Recommended publications
  • WO 2017/048702 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
    [Show full text]
  • The Single Cyclic Nucleotide-Specific Phosphodiesterase of the Intestinal Parasite Giardia Lamblia Represents a Potential Drug Target
    RESEARCH ARTICLE The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target Stefan Kunz1,2*, Vreni Balmer1, Geert Jan Sterk2, Michael P. Pollastri3, Rob Leurs2, Norbert MuÈ ller1, Andrew Hemphill1, Cornelia Spycher1¤ a1111111111 1 Institute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland, 2 Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute of Molecules, Medicines and Systems (AIMMS), Vrije a1111111111 Universiteit Amsterdam, Amsterdam, The Netherlands, 3 Department of Chemistry and Chemical Biology, a1111111111 Northeastern University, Boston, Massachusetts, United States of America a1111111111 a1111111111 ¤ Current address: Euresearch, Head Office Bern, Bern, Switzerland * [email protected] Abstract OPEN ACCESS Citation: Kunz S, Balmer V, Sterk GJ, Pollastri MP, Leurs R, MuÈller N, et al. (2017) The single cyclic Background nucleotide-specific phosphodiesterase of the Giardiasis is an intestinal infection correlated with poverty and poor drinking water quality, intestinal parasite Giardia lamblia represents a potential drug target. PLoS Negl Trop Dis 11(9): and treatment options are limited. According to the Center for Disease Control and Preven- e0005891. https://doi.org/10.1371/journal. tion, Giardia infections afflict nearly 33% of people in developing countries, and 2% of the pntd.0005891 adult population in the developed world. This study describes the single cyclic nucleotide- Editor: Aaron R. Jex, University of Melbourne, specific phosphodiesterase (PDE) of G. lamblia and assesses PDE inhibitors as a new gen- AUSTRALIA eration of anti-giardial drugs. Received: December 5, 2016 Accepted: August 21, 2017 Methods Published: September 15, 2017 An extensive search of the Giardia genome database identified a single gene coding for a class I PDE, GlPDE.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Penile Injection Therapy | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Penile Injection Therapy This information will help you learn to inject medication into your penis. This is called penile injection therapy. Penile injections can help you achieve an erection if you have erectile dysfunction (ED). Read this resource carefully before starting injection therapy. If you do not follow the instructions in this resource, your doctor or APP may stop prescribing your penile injection medications and supplies. About Penile Injection Therapy The tissue that causes you to get an erection (erectile tissue) is a muscle. Going long periods of time without an erection is unhealthy for erectile tissue and may damage it. We believe having erections keeps erectile tissue healthy. A penile injection helps you have an erection. It works best if it’s given about 5 to 15 minutes before you want an erection. Penile Injection Therapy 1/19 Giving Yourself the Injection Your advanced practice provider (APP) will review the instructions below with you. Generally, the training for the injections takes 2 office visits. Please be aware that each visit may take up to 1 hour, so you should plan your schedule on the day of your appointment. Use this resource to help you the first few times you inject on your own. Do not take the following medications within 18 hours of injecting (before or after): Sildenafil (Viagra®) - 20 mg to 100 mg Vardenafil (Levitra®) - 10 mg to 20 mg Avanafil (Stendra®) - 50 mg to 200 mg If you take tadalafil (Cialis®) 10 mg or 20 mg, do not inject within 72 hours (3 days) of taking the medication.
    [Show full text]
  • Call for Methods
    CALL FOR METHODS Methods for Identification, Determination, or Screening Methods for PDE5 Inhibitors AOAC INTERNATIONAL invites method developers to submit methods for consideration and possible evaluation through the AOAC Official MethodsSM program. Prospective methods may be qualitative, identification methods, and/or screening methods for phosphodiesterase type 5 inhibitors (PDE5 inhibitors) in dietary ingredients and supplements. OBJECTIVE: The objective of this call for methods is to select and evaluate methods that can be used for routine surveillance of dietary ingredients. Acceptable methods must be reliable and reproducible when used by trained analysts in accredited laboratories. Interested method developers should provide a description of their proposed method and data characterizing the analytical performance of the proposed method. For the purpose of this Call-for-Methods, PDE5 inhibitors are defined as avanafil, lodenafil carbonate, mirodenafil, sildenafill, tadalafil, udenafil, or vardenafil; or any of their analogs. Any analytical technique that measures the analytes of interest and meets the method performance requirements specified in the SMPR will be considered. It is acceptable to have a different analytical method for each class of analytes. Applicable SMPRs: • View AOAC 2014.010 – Methods for the Identification of PDE5 Inhibitors • View AOAC SMPR 2014.011 – Methods for the Determination of PDE5 Inhibitors • View AOAC SMPR 2014.012 – Screening Methods for PDE5 Inhibitors Submit Your Method AOAC INTERNATIONAL METHOD SUBMISSION PROCESS: AOAC invites method authors to submit their methods with no fee required. Interested method authors or developers should provide a copy of their proposed method, as well as any available data characterizing the analytical performance and scientific validity of the method in AOAC format.
    [Show full text]
  • Gastroesophageal Reflux Disease (GERD)
    Guidelines for Clinical Care Quality Department Ambulatory GERD Gastroesophageal Reflux Disease (GERD) Guideline Team Team Leader Patient population: Adults Joel J Heidelbaugh, MD Objective: To implement a cost-effective and evidence-based strategy for the diagnosis and Family Medicine treatment of gastroesophageal reflux disease (GERD). Team Members Key Points: R Van Harrison, PhD Diagnosis Learning Health Sciences Mark A McQuillan, MD History. If classic symptoms of heartburn and acid regurgitation dominate a patient’s history, then General Medicine they can help establish the diagnosis of GERD with sufficiently high specificity, although sensitivity Timothy T Nostrant, MD remains low compared to 24-hour pH monitoring. The presence of atypical symptoms (Table 1), Gastroenterology although common, cannot sufficiently support the clinical diagnosis of GERD [B*]. Testing. No gold standard exists for the diagnosis of GERD [A*]. Although 24-hour pH monitoring Initial Release is accepted as the standard with a sensitivity of 85% and specificity of 95%, false positives and false March 2002 negatives still exist [II B*]. Endoscopy lacks sensitivity in determining pathologic reflux but can Most Recent Major Update identify complications (eg, strictures, erosive esophagitis, Barrett’s esophagus) [I A]. Barium May 2012 radiography has limited usefulness in the diagnosis of GERD and is not recommended [III B*]. Content Reviewed Therapeutic trial. An empiric trial of anti-secretory therapy can identify patients with GERD who March 2018 lack alarm or warning symptoms (Table 2) [I A*] and may be helpful in the evaluation of those with atypical manifestations of GERD, specifically non-cardiac chest pain [II B*]. Treatment Ambulatory Clinical Lifestyle modifications.
    [Show full text]
  • Phosphodiesterase (PDE)
    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
    [Show full text]
  • (Medical and Mechanical) Treatment of Erectile Dysfunction
    130 SOP Conservative (Medical and Mechanical) Treatment of Erectile Dysfunctionjsm_12023 130..171 Hartmut Porst, MD,* Arthur Burnett, MD, MBA, FACS,† Gerald Brock, MD, FRCSC,‡ Hussein Ghanem, MD,§ Francois Giuliano, MD,¶ Sidney Glina, MD,** Wayne Hellstrom, MD, FACS,†† Antonio Martin-Morales, MD,‡‡ Andrea Salonia, MD,§§ Ira Sharlip, MD,¶¶ and the ISSM Standards Committee for Sexual Medicine *Private Urological/Andrological Practice, Hamburg, Germany; †The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA; ‡Division of Urology, University of Western, ON, Canada; §Sexology & STDs, Cairo University, Cairo, Egypt; ¶Neuro-Urology-Andrology Unit, Department of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, Garches, France; **Instituto H.Ellis, São Paulo, Brazil; ††Department of Urology, Section of Andrology and Male Infertility, Tulane University School of Medicine, New Orleans, LA, USA; ‡‡Unidad Andrología, Servicio Urología Hospital, Regional Universitario Carlos Haya, Málaga, Spain; §§Department of Urology & Urological Reseach Institute (URI), Universiti Vita Saluta San Raffaele, Milan, Italy; ¶¶University of California at San Francisco, San Francisco, CA, USA DOI: 10.1111/jsm.12023 ABSTRACT Introduction. Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male self-esteem and nearly all life domains including interper- sonal, family, and business relationships. Aim. The aim of this study
    [Show full text]
  • The Current Treatment of Erectile Dysfunction Maria Isabela Sarbu Carol Davila University, Department of Dermatology and Venereology, Isabela [email protected]
    Journal of Mind and Medical Sciences Volume 3 | Issue 2 Article 4 2016 The current treatment of erectile dysfunction Maria Isabela Sarbu Carol Davila University, Department of Dermatology and Venereology, [email protected] Mircea Tampa Carol Davila University, Department of Dermatology and Venereology Mădălina I. Mitran Victor Babes Hospital for Infectious and Tropical Diseases, Department of Dermatology and Venereology Cristina I. Mitran Victor Babes Hospital for Infectious and Tropical Diseases, Department of Dermatology and Venereology Vasile Benea Victor Babes Hospital for Infectious and Tropical Diseases, Department of Dermatology and Venereology See next page for additional authors Follow this and additional works at: http://scholar.valpo.edu/jmms Part of the Endocrine System Diseases Commons, Marriage and Family Therapy and Counseling Commons, Psychiatry and Psychology Commons, Reproductive and Urinary Physiology Commons, and the Urology Commons Recommended Citation Sarbu, Maria Isabela; Tampa, Mircea; Mitran, Mădălina I.; Mitran, Cristina I.; Benea, Vasile; and Georgescu, Simona R. (2016) "The current treatment of erectile dysfunction," Journal of Mind and Medical Sciences: Vol. 3 : Iss. 2 , Article 4. Available at: http://scholar.valpo.edu/jmms/vol3/iss2/4 This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at [email protected]. The current treatment of erectile dysfunction Authors Maria Isabela Sarbu, Mircea Tampa, Mădălina I. Mitran, Cristina I. Mitran, Vasile Benea, and Simona R. Georgescu This review article is available in Journal of Mind and Medical Sciences: http://scholar.valpo.edu/jmms/vol3/iss2/4 J Mind Med Sci.
    [Show full text]
  • Can PDE Inhibition Improve Cognition? : Translational Insights
    Can PDE inhibition improve cognition? : Translational insights Citation for published version (APA): Reneerkens, O. A. H. (2013). Can PDE inhibition improve cognition? : Translational insights. Maastricht University. https://doi.org/10.26481/dis.20130418or Document status and date: Published: 01/01/2013 DOI: 10.26481/dis.20130418or Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement: www.umlib.nl/taverne-license Take down policy If you believe that this document breaches copyright please contact us at: [email protected] providing details and we will investigate your claim.
    [Show full text]
  • Pharmaco-Induced Erections for Penile Color-Duplex Ultrasound: Oral PDE5 Inhibitors Or Intracavernosal Injection?
    International Journal of Impotence Research (2012) 24, 191 -- 195 & 2012 Macmillan Publishers Limited All rights reserved 0955-9930/12 www.nature.com/ijir ORIGINAL ARTICLE Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection? Y Yang1,2, J-l Hu1,2,4,YMa1,2, H-x Wang1,2, Z Chen3, J-g Xia3, Y-x Wang1,2, Y-r Huang1,2 and B Chen1,2 To prospectively compare the clinical responses and penile color-duplex ultrasound (PCDU) results of oral PDE5 inhibitors (PDE5-Is) with papaverine intracavernosal injection (ICI) and to evaluate whether PDE5-Is could be used as alternatives to vasoactive agent injections, 25 ED patients underwent PCDU three times with an interval of at least 1 week, using different pharmacological induction: ICI mode (30--60 mg papaverine), sildenafil mode (100 mg sildenafil) and tadalafil mode (20 mg tadalafil). The preference of the patients was collected when all tests were completed. No significant differences were found in peak systolic velocity and acceleration time among all three modes. However for the ICI mode, end diastolic velocity of the right cavernosal artery was significantly higher than those of the sildenafil and tadalafil modes 5 min after erection induction, and at 15 min it became lower than those of two PDE5-I modes. Consequently, resistance index of the right cavernosal artery in ICI mode was reversed at 5 and 15 min. In all, 60.0 and 56.0% patients managed to reach full erection in PDE5-Is modes, which was significantly lower than in ICI mode (80.0%).
    [Show full text]
  • Papaverine Hydrochloride Injection, Solution American Regent, Inc
    PAPAVERINE HYDROCHLORIDE- papaverine hydrochloride injection, solution American Regent, Inc. Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- PAPAVERINE HYDROCHLORIDE INJECTION, USP Rx Only This product is to be used by or under the direction of a physician. Each vial contains a sufficient amount to permit withdrawal and administration of the volume specified on the label. DESCRIPTION Papaverine Hydrochloride, USP, is the hydrochloride of an alkaloid obtained from opium or prepared synthetically. It belongs to the benzylisoquinoline group of alkaloids. It does not contain a phenanthrene group as do morphine and codeine. Papaverine Hydrochloride, USP, is 6,7-dimethoxy-1- veratrylisoquinoline hydrochloride and contains, on the dried basis, not less than 98.5% of C20H21NO4•HCI. The molecular weight is 375.85. The structural formula is as shown. Papaverine Hydrochloride occurs as white crystals or white crystalline powder. One gram dissolves in about 30 mL of water and in 120 mL of alcohol. It is soluble in chloroform and practically insoluble in ether. Papaverine Hydrochloride Injection, USP, is a clear, colorless to pale-yellow solution. Papaverine Hydrochloride, for parenteral administration, is a smooth-muscle relaxant that is available in vials containing 30 mg/mL. Each vial also contains edetate disodium 0.005%. The 10 mL vials also contain chlorobutanol 0.5% as a preservative. pH may be adjusted with sodium citrate and/or citric acid. CLINICAL PHARMACOLOGY The most characteristic effect of papaverine is relaxation of the tonus of all smooth muscle, especially when it has been spasmodically contracted.
    [Show full text]